Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021), Nature Medicine

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Dejnirattisai W. et al, (2021)

Childhood Invasive Bacterial Disease in Kathmandu, Nepal (2005-2013).

Carter MJ. et al, (2021), Pediatr Infect Dis J

The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis.

Oguti B. et al, (2021), Vaccine

Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study.

Meiring JE. et al, (2021), Lancet Glob Health, 9, e1688 - e1696

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.

Hillson K. et al, (2021), Lancet, 398, 1683 - 1684

Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine.

Aguas R. et al, (2021), Nat Commun, 12

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.

Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568

Collection devices to reduce contamination in urine samples provided for diagnosis of uncomplicated urinary tract infection: a single blind randomised controlled trial.

Hayward G. et al, (2021), Br J Gen Pract

Corrigendum to: Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.

Theiss-Nyland K. et al, (2021), Clin Infect Dis

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.

Clemens SAC. et al, (2021), Nat Commun, 12

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.

Swanson PA. et al, (2021), Science translational medicine, eabj7211 - eabj7211

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.

Feng S. et al, (2021), Nat Med

Diagnostic accuracy of FEVER-Pain and centor criteria for bacterial throat infection in adults with sore throat: a secondary analysis of a randomised controlled trial.

Seeley A. et al, (2021), BJGP Open

Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal.

Shrestha S. et al, (2021), J Infect Dis, 224, S267 - S274

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

EWER K. et al, (2021), The Lancet

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.

Madhi SA. et al, (2021), Lancet HIV, 8, e568 - e580

A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance data.

Phillips MT. et al, (2021), Stat Med

Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.

Qadri F. et al, (2021), Lancet

Load More

Include forthcoming?